Andrew M Brunner MD

PubMed

• 1 citations
  Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
  Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang
  Blood. 2025-03-27
• Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults.
  Philip C Amrein, Frederic I Preffer, Geoffrey Fell, Eyal C Attar, Rupa Narayan
  Leukemia & Lymphoma. 2025-03-12
• Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms.
  Savanah D Gisriel, Fnu Aakash, John M Bennett, Robert P Hasserjian, Sanam Loghavi
  Archives of Pathology & Laboratory Medicine. 2025-03-10

Journal Articles

• Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia  
  Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology

Abstracts/Posters

• Results of a Clinical Trial of H3B-8800, a Splicing Modulator, in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic...
  Andrew M. Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration
  Andrew M. Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...
  Andrew M. Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Andrew Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Andrew Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
  Andrew Brunner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018